Literature DB >> 9241243

In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells.

M K Bijsterbosch1, M Manoharan, E T Rump, R L De Vrueh, R van Veghel, K L Tivel, E A Biessen, C F Bennett, P D Cook, T J van Berkel.   

Abstract

Systemically administered phosphorothioate antisense oligodeoxynucleotides can specifically affect the expression of their target genes, which affords an exciting new strategy for therapeutic intervention. Earlier studies point to a major role of the liver in the disposition of these oligonucleotides. The aim of the present study was to identify the cell type(s) responsible for the liver uptake of phosphorothioate oligodeoxynucleotides and to examine the mechanisms involved. In our study we used ISIS-3082, a phosphorothioate antisense oligodeoxynucleotide specific for murine ICAM-1. Intravenously injected [3H]ISIS-3082 (dose: 1 mg/kg) was cleared from the circulation of rats with a half-life of 23.3+/-3.8 min. At 90 min after injection (>90% of [3H]ISIS-3082 cleared), the liver contained the most radioactivity, whereas the second-highest amount was recovered in the kidneys (40.5+/-1.4% and 17.9+/-1.3% of the dose, respectively). Of the remaining tissues, only spleen and bone marrow actively accumulated [3H]ISIS-3082. By injecting different doses of [3H]ISIS-3082, it was found that uptake by liver, spleen, bone marrow, and kidneys is saturable, which points to a receptor-mediated process. Subcellular fractionation of the liver indicates that ISIS-3082 is internalized and delivered to the lysosomes. Liver uptake occurs mainly (for 56.1+/-3.0%) by endothelial cells, whereas parenchymal and Kupffer cells account for 39.6+/-4.5 and 4.3+/-1.7% of the total liver uptake, respectively. Preinjection of polyinosinic acid substantially reduced uptake by liver and bone marrow, whereas polyadenylic acid was ineffective, which indicates that in these tissues scavenger receptors are involved in uptake. Polyadenylic acid, but not polyinosinic acid, reduced uptake by kidneys, which suggests renal uptake by scavenger receptors different from those in the liver. We conclude that scavenger receptors on rat liver endothelial cells play a predominant role in the plasma clearance of ISIS-3082. As scavenger receptors are also expressed on human endothelial liver cells, our findings are probably highly relevant for the therapeutic application of phosphorothioate oligodeoxynucleotides in humans. If the target gene is not localized in endothelial liver cells, the therapeutic effectiveness might be improved by developing delivery strategies that redirect the oligonucleotides to the actual target cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241243      PMCID: PMC146893          DOI: 10.1093/nar/25.16.3290

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  38 in total

1.  Expression cloning of SR-BI, a CD36-related class B scavenger receptor.

Authors:  S L Acton; P E Scherer; H F Lodish; M Krieger
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

2.  Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells.

Authors:  H S Lee; H I Koh
Journal:  Lab Invest       Date:  1994-08       Impact factor: 5.662

Review 3.  Current concepts in antisense drug design.

Authors:  J F Milligan; M D Matteucci; J C Martin
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

4.  Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.

Authors:  S M Stepkowski; Y Tu; T P Condon; C F Bennett
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

5.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.

Authors:  H Sands; L J Gorey-Feret; A J Cocuzza; F W Hobbs; D Chidester; G L Trainor
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

6.  Tritium labeling of antisense oligonucleotides by exchange with tritiated water.

Authors:  M J Graham; S M Freier; R M Crooke; D J Ecker; R N Maslova; E A Lesnik
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

Review 7.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Authors:  C A Stein; Y C Cheng
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

Review 8.  Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP).

Authors:  M Krieger; J Herz
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

9.  Acetyl-low density lipoprotein receptors on rat mesangial cells.

Authors:  K Suzaki; S Kobori; M Ide; T Sasahara; M Sakai; T Toyonaga; M Shinohara; A Miyazaki; S Horiuchi; H Takeda
Journal:  Atherosclerosis       Date:  1993-07       Impact factor: 5.162

10.  Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices.

Authors:  A M Pearson; A Rich; M Krieger
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

View more
  39 in total

Review 1.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 3.  MicroRNAs challenge the status quo of therapeutic targeting.

Authors:  Danish Sayed; Shweta Rane; Maha Abdellatif
Journal:  J Cardiovasc Transl Res       Date:  2008-09-09       Impact factor: 4.132

4.  Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles.

Authors:  Pinal C Patel; David A Giljohann; Weston L Daniel; Dan Zheng; Andrew E Prigodich; Chad A Mirkin
Journal:  Bioconjug Chem       Date:  2010-11-11       Impact factor: 4.774

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

6.  Glyco-poly-l-lysine is better than liposomal delivery of exogenous genes to rat of liver.

Authors:  Chang-Qing Yang; Ji-Yao Wang; Bo-Ming He; Jian-Jun Liu; Jin-Sheng Guo
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 7.  Role of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Oxidative Stress-Associated Metabolic Diseases.

Authors:  Seonwook Kim; Venkateswaran Subramanian; Ahmed Abdel-Latif; Sangderk Lee
Journal:  Metab Syndr Relat Disord       Date:  2020-02-20       Impact factor: 1.894

8.  Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells.

Authors:  P de Diesbach; C Berens; F N'Kuli; M Monsigny; E Sonveaux; R Wattiez; P J Courtoy
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

9.  Use of a Pteridine Moiety to Track DNA Uptake in Cells.

Authors:  Justin A Costa; Edgar Leal-Pinto; Scott C Henderson; Troy Zabel; Mary E Hawkins; Basil Hanss
Journal:  Pteridines       Date:  2013-08       Impact factor: 0.581

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.